BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30910850)

  • 1. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
    Feng X; Li L; Wang L; Luo S; Bai X
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
    Li N; Gou JH; Xiong J; You JJ; Li ZY
    BMC Cancer; 2020 Mar; 20(1):222. PubMed ID: 32178630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target.
    Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y
    Front Oncol; 2019; 9():557. PubMed ID: 31380263
    [No Abstract]   [Full Text] [Related]  

  • 4. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.
    Zhu W; Niu J; He M; Zhang L; Lv X; Liu F; Jiang L; Zhang J; Yu Z; Zhao L; Bi J; Yan Y; Wei Q; Huo H; Fan Y; Chen Y; Ding J; Wei M
    J Transl Med; 2019 Aug; 17(1):259. PubMed ID: 31395064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.
    Sun P; Song Y; Liu D; Liu G; Mao X; Dong B; Braicu EI; Sehouli J
    Sci Rep; 2018 Sep; 8(1):13483. PubMed ID: 30194340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
    Zhao H; Li N; Pang Y; Zhao J; Wu X
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.
    Kielbik M; Szulc-Kielbik I; Klink M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
    Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
    Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J; Park SY; Kim JH
    Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
    Tang W; Ren A; Xiao H; Sun H; Li B
    Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
    Wu GJ; Zeng GF
    BMC Cancer; 2016 Feb; 16():136. PubMed ID: 26906545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
    Zeng S; Liu S; Feng J; Gao J; Xue F
    Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR; Carey DJ; Gogoi R
    BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.